Abstract
We have made substantial progress in developing cancer treatments that target specific molecular vulnerabilities in an increasing number of cancer types.1 Interrogation of complex genomic, transcriptomic, and metabolomic (referred to as omics) profiles, integrated with comprehensive clinical data, represents the essential next step to inform the development and application of selective approaches to cancer prevention, diagnosis, and treatment.2 However, the majority of patients with cancer around the world, and particularly those living in resource-limited settings, cannot access molecular testing and targeted therapies due to regulatory, financial, logistical, educational, and clinical barriers.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
